Key Developments: ARIAD Pharmaceuticals Inc (ARIA.O)

ARIA.O on Nasdaq

7.22USD
19 Dec 2014
Price Change (% chg)

$0.61 (+9.23%)
Prev Close
$6.61
Open
$6.66
Day's High
$7.32
Day's Low
$6.59
Volume
11,391,414
Avg. Vol
6,905,194
52-wk High
$9.83
52-wk Low
$4.80

Search Stocks

Latest Key Developments (Source: Significant Developments)

Ariad and STA announces approval of Iclusig (Ponatinib) in Australia
Monday, 24 Nov 2014 07:35am EST 

Ariad Pharmaceuticals Inc and Specialised Therapeutics Australia Pty Ltd:Receives marketing approval of Iclusig (ponatinib) in Australia by the Therapeutic Goods Administration (TGA).Commercial launch of Iclusig is expected to occur early in 2015.  Full Article

Ariad Pharmaceuticals Inc announces recommendation for Iclusig by Pharmacovigilance Risk Assessment Committee of the European Medicines Agency
Friday, 10 Oct 2014 07:44am EDT 

Ariad Pharmaceuticals Inc:Says Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded its review of Iclusig (ponatinib) under the Article 20 referral procedure.Recommends that Iclusig continue to be used in Europe in accordance with its already approved indications.  Full Article

Ariad and Bellicum announces revised license agreement for ARIAD's Cell-Signaling Technology
Monday, 6 Oct 2014 07:35am EDT 

Ariad Pharmaceuticals Inc:Says Bellicum Pharmaceuticals, Inc. and Ariad Pharmaceuticals, Inc. announces restructuring of their license agreement for Ariad's cell-signaling technology.Ariad will receive $50 mln in exchange for fully paid up license to this technology and return of its equity stake in closely held Bellicum.The scope of license and field of use were also expanded as part of amendment.Under terms of revised agreement, Ariad will receive $50 mln in three installments: $15 mln upon signing of the agreement, $20 mln by June 30, 2015, and $15 mln by June 30, 2016.The last payment may be accelerated to the fourth quarter of 2015 under certain circumstances.Says restructured agreement gives Bellicum worldwide exclusive license to Ariad's cell-signaling technology for broad use in human cell therapies for all diseases on royalty- and milestone-free basis.  Full Article

Ariad Pharmaceuticals's AP26113 receives FDA breakthrough therapy designation
Thursday, 2 Oct 2014 07:55am EDT 

ARIAD Pharmaceuticals Inc:Says that it has received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who are resistant to crizotinib.Says this designation is based on results from the ongoing Phase 1/2 trial that show sustained anti-tumor activity of AP26113 in patients with ALK+ NSCLC, including patients with active brain metastases.  Full Article

ARIAD Pharmaceuticals Inc announces commercial agreement for Iclusig (Ponatinib) in Israel
Tuesday, 5 Aug 2014 07:35am EDT 

ARIAD Pharmaceuticals Inc:Says it has granted Medison exclusive rights to commercialize Iclusig (ponatinib) in Israel in patients with Philadelphia-positive (Ph+) leukemias.ARIAD Pharmaceuticals (Israel) Ltd will be the Marketing Authorization Holder (MAH) of Iclusig in Israel, and Medison will be responsible for sales and marketing, medical affairs, regulatory support, as well as obtaining, in collaboration with ARIAD, the pricing and reimbursement approval of Iclusig.  Full Article

ARIAD Pharmaceuticals Inc prices $200 mln offering of convertible senior notes
Thursday, 12 Jun 2014 09:15am EDT 

ARIAD Pharmaceuticals Inc:Prices of $200 mln aggregate principal amount of its 3.625 pct convertible senior notes due 2019 in private placement.ARIAD also granted the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $30 mln aggregate principal amount of notes on same terms and conditions.Expects to use th proceeds of for its operations, global development of its other product candidates, discovery and for other general corporate purposes, including.  Full Article

ARIAD Pharmaceuticals announces proposed $175 mln offering of convertible senior notes due 2019
Wednesday, 11 Jun 2014 04:01pm EDT 

ARIAD Pharmaceuticals Inc:Announced its intention to offer, subject to market and other conditions, $175 million aggregate principal amount of convertible senior notes due 2019.Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.Intends to grant the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $50 million aggregate principal amount of the Notes on the same terms and conditions.Intends to grant the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $50 million aggregate principal amount of the Notes on the same terms and conditions.  Full Article

ARIAD Pharmaceuticals, Inc announces initiation of pivotal phase 2 ALTA trial of AP26113 in patients with non-small cell lung cancer
Monday, 24 Mar 2014 07:35am EDT 

ARIAD Pharmaceuticals, Inc:Initiation of pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib.ALTA ( A LK in L ung Cancer T rial of A P26113) trial is designed to determine safety and efficacy of AP26113 in refractory NSCLC patients who test positive for anaplastic lymphoma kinase (ALK+) oncogene.  Full Article

Faruqi & Faruqi, LLP files class action lawsuit against ARIAD Pharmaceuticals Inc
Friday, 6 Dec 2013 11:00pm EST 

Faruqi & Faruqi, LLP:Says that it has filed a class action lawsuit in the United States District Court for the District of Massachusetts on behalf of investors who purchased or otherwise acquired ARIAD Pharmaceuticals Inc securities between Dec. 12, 2011 and Oct. 17, 2013, inclusive and suffered damages as a result.Says that complaint alleges that defendants knew or recklessly failed to inform investors that the clinical data from the pivotal Phase 2 PACE trial of ARIAD's leukemia drug Iclusig demonstrated significant cardiovascular side effects in patients treated with the drug.Says such as arterial thrombotic events and strokes, before and during the class period.Says as a result, defendants' statements regarding the safety, outlook, and commercial prospects for Iclusig were materially false and misleading at all relevant times.  Full Article

Levi & Korsinsky, LLP Announces class action against Ariad Pharmaceuticals Inc
Thursday, 5 Dec 2013 06:00pm EST 

Levi & Korsinsky, LLP:Says class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased ARIAD Pharmaceuticals, Inc. stock between Dec. 12, 2011 and Oct. 8.Says complaint alleges that throughout the Class Period defendants made false and misleading statements regarding the safety and efficacy of the leukemia drug Iclusig.  Full Article

UK Stocks-Factors to watch on Thursday, Dec. 4

LONDON, Dec 4 - Britain's FTSE 100 index is seen opening up 11 to 13 points, or 0.2 percent higher, on Thursday, according to financial bookmakers. For more on the factors affecting European stocks, please click on

Search Stocks